Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Allergan’s Nasal Spray For Frequent Nighttime Urination Gets Cautious Panel Nod

Executive Summary

Desmopressin's limited efficacy over placebo doesn't dissuade FDA's advisory committee, which votes 14 to 4 in favor of approval even as many suggest indication be narrowed.

Advertisement

Related Content

Allergan Exits Noctiva Partnership With Serenity Just As FDA Approves Controversial Drug
Desmopressin Battle: Ferring Asks FDA To Reject Serenity's Nocturia Drug
3Q Pharma Results Preview: Pfizer, Gilead, Allergan, Valeant, AstraZeneca
Keeping Track: Oncology Approvals And Responses To Complete Response Letters
Recent And Upcoming FDA Advisory Committees
Allergan Nasal Spray For Frequent Nighttime Urination Faces Review Hurdles

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS119358

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Add a personalized Question to your Analyst

Cancel